Screener / SEC EDGAR /CIK 0001088856 /10-K filed Feb 24, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Corcept Therapeutics Inc CORT

Compare with peers Embed
The 10-K against last year's

136 changes: 45 added, 5 removed, 85 reworded, 1 quiet changes

10-K Feb 24, 2026 vs Feb 26, 2025

10-K 0001628280-26-011091 (Feb 24, 2026) vs 10-K 0001628280-25-008167 (Feb 26, 2025)

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

176 paragraphs · 29 new · 53 reworded · 4 gone · 10-K Feb 24, 2026 against Feb 26, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 37 · 47% changed Every version of it
We make grants to independent charitable foundations that help financially needy patients with their premium, co-pay, and co-insurance obligations with respect to their hypercortisolism treatment, regardless of whether that treatment includes one of our Products. There has been enhanced scrutiny of company-sponsored patient assistance programs, including insurance premium and co-pay assistance programs and donations to third-party charities that provide such assistance. As a result of this scrutiny, these assistance programs and charities may decide to reduce or eliminate entirely the assistance they provide to patients, which could result in fewer patients receiving the financial support they need to cover the cost of their hypercortisolism care, including the cost of medication, which may include one of our Products.
Paragraph 143 · 46% changed Every version of it
Steps taken by the presidential administration in the United States have caused great uncertainty regarding the continuity of government funding, policies and operations. The scope and direction of the administration’s policies and their implementation are unpredictable. New policies may be adopted or actions taken, without notice, that adversely affect our commercial efforts or make it more challenging or costly to develop our product candidates. Significant cuts or disruptions to government employment and spending may delay review of our NDA for relacorilant as a treatment for patients with hypercortisolism or constrain our ability to advance our other clinical development programs and the development programs of our academic collaborators. The imposition of tariffs such as the administration has threatened to impose on materials we or our vendors and collaborators use to conduct experiments or to make our Products or product candidates would have increased our costs and may increase them further. The United States’ tariff regime and the tariff regime of its trading partners are in constant flux. Although we monitor the situation closely, the tariffs that may affect our cost of doing business. business are difficult to predict. It is unlikely that we will be able to anticipate new trade measures or mitigate their impacts, which could be material. Additionally, the laws and regulations governing our operations, as well as the application of such those laws and regulations, may change abruptly. without notice. Failure by us or our vendors to comply with new laws or regulations, whether by us regulations or by our vendors, as well as to respond in a timely way to abrupt changes in the application of existing laws and regulations, regulations could adversely affect our operations, cash flow and financial condition or otherwise harm our business.
Paragraph 29 · 45% changed Every version of it
The active ingredient In September 2025, the HHS announced it will re-examine the safety of mifepristone for use in our Products, mifepristone, is approved by the FDA in another drug for the termination of early pregnancy. In 2022, There can be no assurance this re-examination will not result in restrictions on the United States Supreme Court published its decision in the case distribution of Dobbs v. Jackson Women’s Health Organization (“Dobbs”), which overturned Roe v. Wade, the 1973 Supreme Court decision that had established a woman’s right to terminate her pregnancy, subject to certain limitations. Dobbs has stimulated many states to enact laws restricting the legality of abortion and mifepristone, including during early pregnancy and under specific conditions of use. More laws banning or heavily restricting termination of pregnancy may be adopted and existing laws may be made more restrictive. On June 13, 2024, in a highly publicized case, the Supreme Court ruled against plaintiffs seeking to restrict access to mifepristone for terminating pregnancy, holding that they lacked standing (i.e., any use, including the right to sue), thus preserving current access to mifepristone. Because the Supreme Court’s decision was made solely on procedural grounds, the ruling does not necessarily foreclose other challenges to the continued availability treatment of mifepristone. The timing and outcome of any subsequent cases, as well as additional legislative changes are uncertain. In addition, heightened patients with hypercortisolism. Heightened public awareness of mifepristone as an abortifacient may draw the attention of hostile federal and state government officials or political activists to our Products – as could additional public debate concerning current or proposed restrictions on the distribution of mifepristone. This may be the case even though (i) our Products are not approved for the termination of pregnancy, (ii) we do not promote it them for that use and (iii) we have taken measures to minimize the chance that it they will accidentally be prescribed to a pregnant woman.
Paragraph 168 · 41% changed Every version of it
Our earnings are subject to federal, state and local taxes. We offset a portion of our earnings using net operating losses and our taxes using research and development tax credits, which reduces the amount of tax we pay. Some jurisdictions require that we pay taxes or fees calculated as a percentage of sales, payroll expense, or other indicia of our activities. Please see “Part IV, Item 15, Notes to Consolidated Financial Statements – Income Taxes.” Changes to existing tax laws could materially increase the amounts we pay, which would reduce our after tax net income.
Paragraph 32 · 40% changed Every version of it
The commercial success of our Products depends on the availability of acceptable pricing and adequate insurance coverage and reimbursement. Government payers, including Medicare, Medicaid and the Veterans Administration, as well as private insurers and health maintenance organizations, are increasingly attempting to contain healthcare costs by limiting reimbursement for medicines. In many foreign markets, drug prices and the profitability of prescription medications are subject to government control. In the United States, we expect that there will continue to be federal and state proposals for similar controls. Also, the trends toward managed health care in the United States and recent laws and legislation intended to increase the public visibility of drug prices and reduce the cost of government and private insurance programs could significantly influence the purchase of health care services and products and may result in lower prices for our Products. If government or private payers cease to provide adequate and timely coverage, pricing and reimbursement for our Products, physicians may not prescribe the medication and patients may not purchase it, even if it is prescribed, or the price we receive may be reduced, which would reduce our revenue.
Paragraph 67 · 38% changed Every version of it
The risk of being found in violation of these laws and regulations is increased by the fact that many of them have not been definitively interpreted by regulatory authorities or the courts and their provisions are open to a variety of interpretations. Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available under them, it is possible that some of our business activities, including our relationships with physicians and other healthcare providers (some of whom recommend, purchase and/or prescribe our Products) and the manner in which we promote our Products, could be subject to challenge and scrutiny. We are also exposed to the risk that our employees, independent contractors, principal investigators, consultants, vendors, distributors and contract research organizations (“CROs”) may engage in fraudulent or other illegal activity. Although we have policies and procedures prohibiting such activity, it is not always possible to identify and deter misconduct and the precautions we take may not be effective in controlling unknown risks or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with applicable laws and regulations.
Paragraph 45 · 37% changed Every version of it
Since 2012, a medication owned by Recordati-S.p.A. has marketed the Italian pharmaceutical company Recordati-S.p.A., the injectable somatostatin analogue Signifor® (pasireotide) Injection, has been marketed pasireotide in both the United States and the EU as a treatment for adult patients with Cushing’s disease (a disease, a subset of hypercortisolism). On March 6, hypercortisolism. In 2020, the FDA granted Recordati approval to market another the cortisol synthesis inhibitor, Isturisa® (osilodrostat) tablets, inhibitor osilodrostat to treat patients with Cushing’s disease. Osilodrostat is approved disease, which approval was broadened in the EU for the treatment of April 2025 to include adult patients with any etiology of hypercortisolism.
Paragraph 68 · 35% changed Every version of it
The risk of being found in violation of these laws and regulations is increased by the fact that many of them have not been definitively interpreted by regulatory authorities or the courts and their provisions are open to a variety of interpretations. Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available under them, it is possible that some of our business activities, including our relationships with physicians and other healthcare providers (some of whom recommend, purchase and/or prescribe our Products) and the manner in which we promote our Products, could be subject to challenge and scrutiny. We are also exposed to the risk that our employees, independent contractors, principal investigators, consultants, vendors, distributors and contract research organizations (“CROs”) may engage in fraudulent or other illegal activity. Although we have policies and procedures prohibiting such activity, it is not always possible to identify and deter misconduct and the precautions we take may not be effective in controlling unknown risks or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with applicable laws and regulations.

MD&A

74 paragraphs · 16 new · 41 reworded · 1 gone · 10-K Feb 24, 2026 against Feb 26, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 47 · 42% changed
The Inflation Reduction Act of 2022 (“IRA”) IRA was enacted on August 16, 2022. The IRA includes provisions requiring manufacturers to pay a rebate to the Centers for Medicare & Medicaid Services (“CMS”) CMS if the price of a Medicare Part B or Part D drug increases faster than the rate of inflation. In addition, beginning in 2025, the IRA will also shift shifts a significant portion of the Medicare beneficiary costs currently borne by the government and beneficiaries to manufacturers. We anticipate this provision will limit the revenue we receive from Medicare patients and may materially reduce our profits. The IRA permits CMS to negotiate prices for certain high-expenditure Medicare Part B or Part D drugs.
Paragraph 32 · 41% changed
Notably, As was the case in ROSELLA, the addition of relacorilant to treatment with nab-paclitaxel did not create an additional adverse event burden for patients. Safety increase patients’ safety burden. The safety and tolerability of relacorilant and nab-paclitaxel combination treatment were was comparable to the safety and tolerability of nab-paclitaxel monotherapy. monotherapy alone.
Paragraph 52 · 41% changed
Net product revenue was $675.0 $761.4 million for the year ended December 31, 2024, 2025, compared to $482.4 $675.0 million and $401.9 $482.4 million for the years ended December 31, 2023 2024 and 2022, 2023, respectively. Higher sales volume accounted for 79.4 percent of the The increase for the year ended December 31, 2024, with the remaining growth 2025 compared to 2024 was driven by a 37.0 percent increase in sales volume, partially offset by a 17.7 percent decrease in average price due to higher sales volume from our authorized generic version of Korlym. The decrease in average price was partially offset by a price increase effective January 1, 2024. of our Products in August 2025. For the year ended December 31, 2025, net product revenue would have been materially higher had our primary specialty pharmacy vendor been able to fully meet demand for our Products.
Paragraph 26 · 36% changed
Relacorilant in Patients with Platinum-Resistant Ovarian Cancer. We are conducting a pivotal Phase 3 trial (“ROSELLA”) of our proprietary, selective cortisol modulator, relacorilant combined with nab-paclitaxel as a treatment for patients with platinum-resistant ovarian cancer. Enrollment in ROSELLA is complete. Three enrolled three hundred eighty-one women with recurrent, platinum-resistant ovarian cancer who were randomized 1:1 to receive either 150 mg of relacorilant intermittently in addition to the chemotherapeutic agent nab-paclitaxel or nab-paclitaxel monotherapy. ROSELLA has dual primary endpoints – progression free survival (“PFS”) and overall survival (“OS”). ROSELLA will have a statistically positive outcome if either endpoint is met. Patients enrolled in ROSELLA were required to have received prior bevacizumab therapy, which is the approved standard of care for patients with platinum-resistant ovarian cancer. Women with a history of tumors that do not respond to initial platinum-based treatments (i.e., women with “primary platinum-refractory” disease) and those who have received more than three prior lines of therapy were excluded.
Paragraph 62 · 32% changed
Interest and other income – Interest and other income for the years ended December 31, 2024, 2025, 2024 and 2023 and 2022 was $21.7 million, $24.5 million, $17.3 million and $3.6 $17.3 million, respectively, and consisted primarily of interest income from marketable securities. The increase decrease for the year ended December 31, 2024 2025 compared to 2023 2024 was due to higher cash market-wide decreases in interest rates and investment balances. foreign currency transaction losses due to unfavorable changes in the U.S. dollar exchange rate to settle foreign currency-denominated monetary assets and liabilities.
Paragraph 42 · 32% changed
ALS, also known as Lou Gehrig’s disease, is a devastating neuromuscular illness. Our selective cortisol modulator dazucorilant improved motor performance and reduced neuroinflammation and muscular atrophy in an animal model of ALS. Following these compelling results, we initiated a Phase 2 trial (“DAZALS”) trial, DAZALS, of dazucorilant in patients with ALS. Two hundred forty-nine patients were randomized on a double-blind basis 1:1:1 to receive either 150 mg of dazucorilant, 300 mg of dazucorilant or placebo daily for 24 weeks. Upon completion of the trial, patients were eligible to enter an open-label, long-term extension study, in which they receive 300 mg of dazucorilant for up to 132 weeks. DAZALS did not meet its primary endpoint, which was the change from baseline in the ALS Functional Rating Scale-Revised (ALSFRS-R) in patients who received dazucorilant compared to those who received placebo. Patients who received dazucorilant also experienced substantially more gastrointestinal upset at the onset of treatment than did those who received placebo. During the 24-week study, no deaths (0/83) were observed in the 300 mg dazucorilant arm, compared to 5 deaths (5/82) in the placebo group (p-value: 0.02). The open-label, long-term extension study, which enrolled 118 patients, will continue. Pursuant to the study protocol, overall survival will be assessed again in March 2025. The FDA has granted dazucorilant Fast Track Designation and orphan drug status for the treatment of ALS in the United States.
Paragraph 48 · 31% changed
The Inflation Reduction Act of 2022 (“IRA”) was enacted on August 16, 2022. The IRA includes provisions requiring manufacturers to pay a rebate to the Centers for Medicare & Medicaid Services (“CMS”) if the price of a Medicare Part B or Part D drug increases faster than the rate of inflation. In addition, beginning in 2025, the IRA will also shift a significant portion of the Medicare beneficiary costs currently formerly borne by the government and beneficiaries to manufacturers. manufacturers in the form of limitations on price increases and rebates paid to the government. We anticipate this provision will limit the revenue we receive from Medicare patients and may materially reduce our profits. profits in 2026 and beyond. The IRA permits CMS to negotiate prices for certain high-expenditure Medicare Part B or Part D drugs.
Paragraph 11 · 30% changed
all of In December 2024, we submitted a NDA to the FDA seeking approval to market relacorilant as a treatment for patients with endogenous hypercortisolism. The NDA was based on positive results from our pivotal GRACE trial, with confirmatory evidence from our Phase 3 GRADIENT trial, our Phase 3 long-term extension study and our Phase 2 study. Patients in these trials, patients trials exhibited clinically meaningful improvements in a wide range of hypercortisolism signs and symptoms, including hypertension, glucose control, weight and body composition. Relacorilant was has been well-tolerated in all of the its clinical trials. Notably, patients did not experience some of the serious adverse events that can arise in patients taking Korlym or other currently approved treatments.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Risk Factors269 words changed in this paragraph; it is 39% similar to last year's version.
We cannot sell a product without the approval of the FDA FDA, EMA or comparable foreign regulatory authority. Obtaining such approval is difficult, uncertain, lengthy and expensive. Failure can occur at any stage. In order to receive FDA approval for a new drug, we must demonstrate to the FDA’s satisfaction that the new drug is safe and effective for its intended use and that our manufacturing processes comply with cGMPs. Our inability or Recent disruptions at the inability of our vendors to comply with applicable FDA and other government agencies caused by changing presidential administrations or funding shortages could hinder their ability to hire, retain or deploy key leadership and other personnel, prevent new or modified product candidates from being developed, reviewed, approved or commercialized in a timely manner or at all, which could negatively impact our business. In addition, policies, regulations, and the type and amount of clinical data that the regulatory requirements can result in delays in or denials authority views as necessary for approval may change during the course of new a product approvals, warning letters, untitled letters, fines, consent decrees restricting or suspending manufacturing operations, injunctions, civil penalties, recall or seizure of products, total or partial suspension of product sales candidate’s clinical development and criminal prosecution. We may seek to commercialize our Products in international markets, which would require us to receive a marketing authorization and, in many cases, pricing approval, from vary among jurisdictions. Even if we believe the appropriate regulatory authorities. Approval procedures vary between countries and can require additional pre-clinical preclinical or clinical studies. Obtaining approval data for our product candidates are promising, such data may take longer than it does in the United States. Although not be sufficient to support approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one or comparable foreign regulatory authority does not ensure approval by others, failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. Any of these or other regulatory actions could materially harm our business and financial condition. authorities.

Source: Item 1A, 10-K 0001628280-26-011091 vs Item 1A, 10-K 0001628280-25-008167

Legal Proceedings185 words changed in this paragraph; it is 46% similar to last year's version.
In March 2019, On February 20, 2026, a purported securities class action complaint was filed in the United States U.S. District Court for the Northern District of California by Nicholas Melucci (Melucci the Allegheny County Employees’ Retirement System (Allegheny County Employees’ Retirement System v. Corcept Therapeutics Incorporated, et al., Case No. 5:19-cv-01372-LHK) (the “Melucci litigation”). 3:26-cv-1525). The complaint named us names Corcept and certain of our its executive officers as defendants asserting violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder and alleged alleges, among other things, that the defendants made or are responsible for making false and materially misleading statements and failed to disclose adverse facts about omissions regarding our business, operations and prospects. NDA for our product candidate, relacorilant, as a treatment for patients with hypercortisolism. The complaint asserted asserts a putative class period extending stemming from August 2, 2017 October 31, 2024, to February 5, 2019 December 30, 2025 and sought seeks damages, attorneys’ fees and costs and unspecified monetary relief, interest and attorneys’ fees. On June 6, 2024, Judge James Donato of the United States District Court for the Northern District of California granted final approval of a settlement resolving all claims in the Melucci litigation (the “Melucci Settlement”). As previously disclosed, the Melucci Settlement required us to make a one-time payment of $14 million for which our insurers reimbursed us in full. On September 6, 2024, Judge Donato approved the Plan of Allocation for payment of the settlement funds to eligible members of the class of plaintiffs. This matter is closed. relief. We will vigorously defend ourselves against this lawsuit.

Source: Item 3, 10-K 0001628280-26-011091 vs Item 3, 10-K 0001628280-25-008167

MD&A128 words changed in this paragraph; it is 62% similar to last year's version.
ALS, also known as Lou Gehrig’s disease, is a devastating neuromuscular illness. Our selective cortisol modulator dazucorilant improved motor performance and reduced neuroinflammation and muscular atrophy in an animal model of ALS. Following these compelling results, we initiated a Phase 2 trial (“DAZALS”) trial, DAZALS, of dazucorilant in patients with ALS. Two hundred forty-nine patients were randomized on a double-blind basis 1:1:1 to receive either 150 mg of dazucorilant, 300 mg of dazucorilant or placebo daily for 24 weeks. Upon completion of the trial, patients were eligible to enter an open-label, long-term extension study, in which they receive 300 mg of dazucorilant for up to 132 weeks. DAZALS did not meet its primary endpoint, which was the change from baseline in the ALS Functional Rating Scale-Revised (ALSFRS-R) in patients who received dazucorilant compared to those who received placebo. Patients who received dazucorilant also experienced substantially more gastrointestinal upset at the onset of treatment than did those who received placebo. During the 24-week study, no deaths (0/83) were observed in the 300 mg dazucorilant arm, compared to 5 deaths (5/82) in the placebo group (p-value: 0.02). The open-label, long-term extension study, which enrolled 118 patients, will continue. Pursuant to the study protocol, overall survival will be assessed again in March 2025. The FDA has granted dazucorilant Fast Track Designation and orphan drug status for the treatment of ALS in the United States.

Source: Item 7, 10-K 0001628280-26-011091 vs Item 7, 10-K 0001628280-25-008167

Accounting Policies113 words changed in this paragraph; it is 39% similar to last year's version.
In November 2023, December 2025, the FASB issued ASU No. 2023-07, 2025-11, which amends ASC 270, Interim Report (“ASC 270”) to improve clarify the disclosures about scope, form, and content of interim financial statements and centralizes interim disclosure requirements within ASC 270. This ASU introduces a public entity’s reportable segments new interim disclosure principle requiring entities to disclose material events and address requests from investors for additional, more detailed information about a reportable segment’s expenses. The standard changes occurring since the last annual reporting period and clarifies the preparation and presentation of condensed interim financial information. This ASU is effective for public companies with annual periods beginning after December 15, 2023, and for interim periods within fiscal years beginning after December 15, 2024, 2027, with early adoption permitted. We adopted are evaluating the effects adoption of this guidance for will have on the annual period ended December 31, 2024. condensed consolidated financial statements.

Source: 10-K text, Note 1 – Basis of Presentation and Summary of Significant Accounting Policies, 10-K 0001628280-26-011091 vs 10-K text, Note 1 – Basis of Presentation and Summary of Significant Accounting Policies, 10-K 0001628280-25-008167

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of CORT's Risk Factors and MD&A, 10-K Feb 24, 2026 against 10-K Feb 26, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
The current Trump administration is pursuing policies to reduce regulations and expenditures across government including at the HHS, the FDA, CMS and related agencies. These actions, presently directed by executive orders or memoranda from the Office of Management and Budget, may propose policy changes that create additional uncertainty for our business. These actions and proposals may, for example, include directives: (1) reducing agency workforce and cutting programs; (2) rescinding a Biden administration executive order tasking the Center for Medicare and Medicaid Innovation, or CMNI, to consider new payment and healthcare models to limit drug spending; (3) eliminating the Biden administration’s executive order that directed the HHS to establishing an AI task force and developing a strategic plan; (4) directing HHS and other agencies to lower prescription drug costs through a variety of initiatives, including by improving upon the Medicare Drug Price Negotiation Program and establishing Most-Favored-Nation pricing for pharmaceutical products; (5) imposing tariffs on imported pharmaceutical products; and (6) directing certain federal agencies to enforce existing law regarding hospital and plan price transparency and by standardizing prices across hospitals and health plans. Congress may introduce and ultimately pass health care related legislation that could impact the drug approval process and make changes to the Medicare Drug Price Negotiation Program created under the IRA. This could lower the price that we receive for any approved product. Any denial in coverage or reduction in reimbursement from Medicare or other government-funded programs may result in a similar denial or reduction in payments from private payors, which may prevent us from being able to generate sufficient revenue, attain profitability or commercialize our product candidates, if approved. Furthermore, on July 4, 2025, legislation commonly referred to as the One Big Beautiful Bill Act was signed into law, which reduced funding to federal healthcare programs and imposed additional requirements to be eligible for healthcare, which may result in decreased access to healthcare, particularly in Medicaid programs.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
We do not currently have nor do we have immediate plans to acquire the infrastructure or internal capability to manufacture our clinical drug supplies for use in the conduct of our clinical trials, and we lack the internal resources and the capability to manufacture any of our product candidates on a clinical or commercial scale. The facilities used by our contract manufacturers to manufacture our product candidates must be approved by the FDA pursuant to inspections that will be conducted after we submit our NDA to the FDA. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
Any replacement of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. In some cases, the technology required to manufacture our product candidates may be unique to the original manufacturer and we may have difficulty transferring such skills or technology to another third party. The
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
process of changing manufacturers is extensive and time-consuming and could cause delays or interruptions in our product candidate supply. Further, if we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with all applicable regulations and guidelines, including cGMPs, and that the post-change material is comparable to pre-change. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supply of our products.
Read it in 10-K Feb 24, 2026 at sec.gov
Show the other 46
AddedRisk Factors
and supportive studies that we consider appropriate and the results are positive, we may not receive regulatory approval and marketing authorization to market our product candidates, which would adversely affect our business, financial condition, results of operations and prospects. Following regulatory approval, there is no assurance of commercial success.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
In addition, the FDA and comparable foreign regulatory authorities may change their policies, issue additional regulations or revise existing regulations, or take other actions, which may prevent or delay approval of our future products under development on a timely basis. There remains substantial uncertainty as to how the current U.S. administration will seek or continue to modify or revise the requirements and policies of the FDA and other regulatory agencies with jurisdiction over our product candidates. State governments may also attempt to address or react to changes at the federal level with changes to their own regulatory frameworks in a manner that is adverse to our operations. This uncertainty could present new challenges or potential opportunities as we navigate the clinical development and approval process for our product candidates. Such policy or regulatory changes through, for example, executive orders or legislation could impose additional requirements upon us that could delay our ability to obtain approvals, increase the costs of compliance or restrict our ability to maintain any marketing authorizations we may have obtained.
Read it in 10-K Feb 24, 2026 at sec.gov
RemovedRisk Factors
Short sellers have, and likely will continue to, attempt to drive down the price of our common stock. Short selling is the practice of selling stock the seller does not own with the intention of buying it back later at a lower price, thereby profiting
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedRisk Factors
as the U.S. Department of Health and Human Services Office of Civil Rights issued a proposed rule that would amend certain security compliance requirements for covered entities and business associates.
Read it in 10-K Feb 26, 2025 at sec.gov
RewordedRisk Factors
Since 2012, a medication owned by Recordati-S.p.A. has marketed the Italian pharmaceutical company Recordati-S.p.A., the injectable somatostatin analogue Signifor® (pasireotide) Injection, has been marketed pasireotide in both the United States and the EU as a treatment for adult patients with Cushing’s disease (a disease, a subset of hypercortisolism). hypercortisolism.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
On March 6, In 2020, the FDA granted Recordati approval to market another the cortisol synthesis inhibitor, Isturisa® (osilodrostat) tablets, inhibitor osilodrostat to treat patients with Cushing’s disease. disease, which approval was broadened in April 2025 to include adult patients with any etiology of hypercortisolism.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
The availability of generic versions of Korlym from Sun or Hikma could materially harm our results of operations and financial condition, even if our on-going appeal against Teva is successful and Teva, Sun and Hikma were required to withdraw their products and pay us damages. condition.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
Failure by us or our vendors to comply with new laws or regulations, whether by us regulations or by our vendors, as well as to respond in a timely way to abrupt changes in the application of existing laws and regulations, regulations could adversely affect our operations, cash flow and financial condition or otherwise harm our business.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
In addition, certain state laws govern the privacy and security of health health-related and other personal information in certain circumstances, some of which are may be more stringent stringent, broader in scope or offer greater individual rights with respect to protected health information than HIPAA and many of which may differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
Further, the California Consumer Privacy Act, which took effect on January 1, 2020, and was later Act (the “CCPA”), revised and expanded amended by the California Privacy Rights Act, collectively Act (the “CPRA” and collectively, the CCPA, “CCPA”), created individual privacy rights for California consumers and increased the privacy and security obligations of entities handling certain personal information as well as limitation on data uses, audit requirements for higher risk data, and opt outs for certain uses of sensitive data.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
The imposition of tariffs such as the administration has threatened to impose on materials we or our vendors and collaborators use to conduct experiments or to make our Products or product candidates would have increased our costs and may increase our cost of doing business. them further.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
Beginning in 2025, the The IRA also shifts a significant portion of the Medicare beneficiary costs from the government and beneficiaries to manufacturers. manufacturers in the form of limitations on price increases and rebates paid to the government.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
The GDPR imposes substantial fines for breaches of data protection requirements, which can be up to four percent of global revenue for the preceding financial year or €20 million, whichever is greater, and it also confers a private right of action on data subjects for breaches of data protection requirements.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
In addition, if Optime Curant has operational difficulties or otherwise becomes unable or unwilling to perform its obligations under our agreement, we may not be able to dispense our Products in a timely manner to some or all of our patients. patients, which may adversely affect our business, results of operations and financial position.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
If we elect, or are required by authorities, to delay, suspend or terminate a clinical trial or commercialization efforts, the commercial prospects of the affected product candidates or products may be harmed and our ability to generate product revenues from them may be delayed or eliminated.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
If Teva’s commercial efforts are successful, they may materially harm our results of operations and financial condition, even if our appeal is successful and Teva is required to withdraw its product and pay us damages. condition.
Read it in 10-K Feb 24, 2026 at sec.gov
Quiet changesRisk Factors
If In addition, if we receive regulatory approval for a product candidate, we will be subject to ongoing requirements and oversight by the FDA and other regulatory authorities, such as continued safety and other reporting requirements and possibly post-approval marketing restrictions and additional costly clinical trials.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
CATALYST’s results were published in Diabetes Care (Buse et al., April 2025 (first phase) and DeFronzo et al., June 2025 (second phase)), the peer-reviewed journal of the American Diabetes Association.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
To determine the prevalence of hypercortisolism in patients with resistant hypertension, we initiated the MOMENTUM trial in March 2025. Resistant hypertension is defined by the American Heart Association as systolic blood pressure greater than 130mm Hg and diastolic blood pressure greater than 80mm Hg despite the use of three or more antihypertensive medications of different classes, including a diuretic. MOMENTUM completed enrollment of over 1,000 patients in December 2025. Enrollment is closed.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
On December 30, 2025, the FDA issued a CRL declining to approve relacorilant. While the letter acknowledged that our GRACE trial had met its primary endpoint and that our GRADIENT trial had provided confirmatory evidence, the FDA stated that additional evidence of efficacy would be required for approval. We are working with the FDA to determine relacorilant’s optimal path to approval.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
Relacorilant in Combination with Chemotherapy. In July 2025, we submitted an NDA seeking approval to market relacorilant plus the chemotherapy medication nab-paclitaxel as a treatment for patients with platinum-resistant ovarian cancer in the United States. In September 2025, the FDA accepted our NDA for filing and assigned a PDUFA date of July 11, 2026. In October 2025, we submitted an MAA to the EMA seeking approval in the European Union. Our NDA and MAA are both based on positive results from our pivotal Phase 3 ROSELLA and Phase 2 trials, in which patients exhibited clinically meaningful improvements in PFS and OS. In both trials, relacorilant was well-tolerated and did not increase the safety burden of patients who took it.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
ROSELLA met its dual primary endpoints – PFS as assessed by blinded independent central review and OS. In March 2025, we announced that ROSELLA had met its PFS endpoint. Patients treated with relacorilant in addition to nab-paclitaxel experienced a clinically and statistically significant 30 percent reduction in risk of disease progression compared to patients treated with nab-paclitaxel alone (hazard ratio: 0.70; p-value: 0.008). PFS improvement as assessed by ROSELLA’s clinical investigators was also positive (hazard ratio: 0.71; p-value: 0.0030). In January 2026, we announced that ROSELLA had met its OS primary endpoint. Patients treated with relacorilant in addition to nab-paclitaxel chemotherapy experienced a clinically and statistically significant 35 percent reduction in the risk of death compared to patients treated with nab-paclitaxel alone (hazard ratio: 0.65; p-value: 0.0004). The median OS for patients receiving relacorilant was 16.0 months, compared to 11.9 months for patients receiving nab-paclitaxel alone. Importantly, both PFS and OS benefits were seen in all clinically relevant patient subgroups, including those with poor prognoses.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
Relacorilant in combination with nab-paclitaxel was well-tolerated, consistent with its known safety profile. Importantly, relacorilant conferred its benefit without increasing the safety burden of the patients who received it. The type, frequency and severity of adverse events in the combination arm were comparable to those in the nab-paclitaxel monotherapy arm.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
In April 2025, we initiated a Phase 2 trial, BELLA, which has three parts. In December 2025, Part A completed enrollment of 95 patients with platinum-resistant ovarian cancer. Part A will evaluate the efficacy and safety of treatment with relacorilant plus nab-paclitaxel and bevacizumab. Part B has a planned enrollment of 90 patients with platinum-sensitive ovarian cancer, whose disease had progressed while receiving treatment with a PARP-inhibitor. Part B will evaluate the efficacy and safety of treatment with relacorilant plus nab-paclitaxel and bevacizumab. Part C has a planned enrollment of 90 patients with endometrial cancer who have received one or two prior lines of therapy. Part C will evaluate the efficacy and safety of treatment with relacorilant plus nab-paclitaxel.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
In December 2025, we initiated a Phase 2 trial, TRIDENT, with a planned enrollment of 50 patients with pancreatic cancer, who have not received prior therapy for metastatic disease. TRIDENT will evaluate the efficacy and safety of treatment with relacorilant plus nab-paclitaxel and gemcitabine.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
In collaboration with the Paris-based academic research cooperative ARCAGY-GINECO, we will initiate, in the first quarter of 2026, a Phase 2 trial, STELLA, in 50 patients with cervical cancer, who have received one or two prior lines of therapy. STELLA will evaluate the efficacy and safety of treatment with relacorilant plus nab-paclitaxel.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
Nenocorilant in Combination with Immunotherapy. Immunotherapy harnesses the body’s immune system to identify and destroy cancer cells. We are testing the potential of our proprietary, selective cortisol modulator, nenocorilant to treat cancer by reducing cortisol-activated immune suppression and thereby help the patient’s immune system reduce or eradicate tumors while
Read it in 10-K Feb 24, 2026 at sec.gov
RemovedMD&A
Relacorilant in Patients with Adrenal Cancer with Cortisol Excess. We have completed an open-label, Phase 1b trial of relacorilant plus the PD-1 checkpoint inhibitor pembrolizumab in 14 patients with metastatic or unresectable adrenal cancer whose tumors produce cortisol. Patients with this form of adrenal cancer virtually never respond to immunotherapy and their disease progresses very rapidly. Our trial sought to test whether adding relacorilant to pembrolizumab therapy would reduce cortisol-activated immune suppression sufficiently to help the patient’s immune system reduce or eradicate the patient’s tumors while also reducing the symptoms of hypercortisolism caused by the tumors’ hypersecretion of cortisol. Although patients exhibited significant improvements in their symptoms of hypercortisolism, such as reductions in hypertension and hyperglycemia, their tumor progression did not slow. The combination of relacorilant with pembrolizumab was well-tolerated. We are evaluating next steps to better understand the role cortisol modulation may play in combination with immunotherapies directed to other tumor types and earlier stages of cancer.
Read it in 10-K Feb 26, 2025 at sec.gov
RewordedMD&A
In the year ended December 31, 2024, 2025, we spent $38.0 $245.9 million acquiring shares of our common stock, comprised of $15.7 $172.9 million pursuant to our Stock Repurchase Program, $17.0 $56.8 million acquiring shares of our common stock in connection with the net exercise of employee and director stock options and $5.3 $16.1 million to satisfy tax withholding requirements from vesting of restricted stock grants, offset by $5.5 million received in connection with our ESPP and $4.2 million net cash received from the exercise of stock options.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
The increase for the year ended December 31, 2024 2025 compared to 2023 2024 was primarily due to increased spending on expenses related to the advancement and completion of our Cushing’s syndrome and Oncology development programs and increased employee compensation expense expenses, partially offset by decreased expenses related to support these activities. development programs that are nearing completion.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
The increase change in income tax expense for the year ended December 31, 2024 2025 resulting in an income tax benefit compared to 2023 an income tax expense in 2024 was primarily due to increased income before income taxes. stock compensation deductions and decreased pretax income.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
The change for the year ended December 31, 2024 2025 compared to 2023 2024 was primarily due to investments in marketable securities during 2024 compared to a higher allocation of cash proceeds from maturities of marketable securities towards cash equivalents to purchase shares in anticipation of the closing of connection with our tender offer during 2023. Stock Repurchase Program.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
We expect our research and development expense to be higher in 2025 2026 than in 2024 2025 as our clinical programs advance and we add initiate new clinical trials, assuming success in our existing trials, and our existing trials enroll more patients. trials.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
The increase for the year ended December 31, 2024 2025 compared to 2023 2024 was primarily due to increased sales and marketing activities and employee compensation expenses to support commercialization of our existing and sales and marketing activities. potential future products.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Women with a history of tumors that do not respond to initial platinum-based treatments (i.e., women with “primary platinum-refractory” disease) and those who have received more than three prior lines of therapy were excluded.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
The increase decrease for the year ended December 31, 2024 2025 compared to 2023 2024 was primarily due to lower net income resulting from higher revenue. operating expenses to support increased sales and marketing activities.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
In For the year ended December 31, 2024, we spent $38.0 million acquiring shares of our common stock, comprised of $15.7 million pursuant to our Stock Repurchase Program, $17.0 million acquiring shares of our common stock in connection with the net exercise of employee and director stock options options, $15.7 million pursuant to our Stock Repurchase Program and $5.3 million to satisfy tax withholding requirements from vesting of restricted stock grants, offset by $5.5 million received in connection with our ESPP and $4.2 million net cash received from the exercise of stock options.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Notably, As was the case in ROSELLA, the addition of relacorilant to treatment with nab-paclitaxel did not create an additional adverse event burden for patients. increase patients’ safety burden.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
The increase of cost of sales as a percentage of revenue for the year ended December 31, 2024 2025 compared to 2023 2024 was primarily due to increased manufacturing and distribution costs. a decrease in the average selling price of our Products.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Patients in GRADIENT who received relacorilant exhibited clinically meaningful and statistically significant improvements in a wide array of hypercortisolism’s signs and symptoms, including hypertension, hyperglycemia, weight and body composition compared to baseline, composition, while patients who received placebo did not.
Read it in 10-K Feb 24, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CORT/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.